OPKO HEALTH, INC. Amends GeneDx Holdings Stake Filing

TL;DR

OPKO HEALTH, INC. updated its filing on GeneDx Holdings. Keep an eye on this.

AI Summary

OPKO HEALTH, INC. has amended its Schedule 13D filing regarding GeneDx Holdings Corp. as of September 18, 2024. The filing indicates a change in beneficial ownership, though specific details on the percentage change or dollar amounts are not provided in this excerpt. OPKO HEALTH, INC. previously operated under the name Sema4 Holdings Corp. and CM Life Sciences, Inc. before its current name.

Why It Matters

This filing update from OPKO HEALTH, INC. signals a potential shift in its investment or control over GeneDx Holdings Corp., which could impact the market perception and strategic direction of both companies.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate significant strategic moves or financial shifts by major holders, warranting close monitoring.

Key Players & Entities

• OPKO HEALTH, INC. (company) — Filing entity
• GeneDx Holdings Corp. (company) — Subject company
• Sema4 Holdings Corp. (company) — Former name of subject company
• CM Life Sciences, Inc. (company) — Former name of subject company

FAQ

Key Financial Figures

• $0.0001 — suer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $31.50 — the open market at prices ranging from $31.50 to $38.59 per share for an aggregate sa
• $38.59 — market at prices ranging from $31.50 to $38.59 per share for an aggregate sale price o
• $12,053,996 — n aggregate sale price of approximately $12,053,996. ITEM 5. Interest in Securities of
• $29.00 — the open market at prices ranging from $29.00 to $38.59 per share for an aggregate sa
• $41,649,375 — n aggregate sale price of approximately $41,649,375. Sales of GeneDx Common Stock prior to

Filing Documents

• opk20240917_sc13da.htm (SC 13D/A) — 85KB
• 0001437749-24-029481.txt ( ) — 87KB

is amended by adding the following paragraph to the end of the item

Item 4 is amended by adding the following paragraph to the end of the item: In a series of transactions between August 26, 2024 and September 18, 2024, OPKO sold a total of 330,472 shares of GeneDx Common Stock on the open market at prices ranging from $31.50 to $38.59 per share for an aggregate sale price of approximately $12,053,996. ITEM 5. Interest in Securities of the Issuer.

is deleted in its entirety and replaced with the following text

Item 5 is deleted in its entirety and replaced with the following text: (a) The Company's beneficial ownership of GeneDx Common Stock is as set forth in the table below: Name and Title of Beneficial Owner Number of Outstanding Shares Beneficially Owned Percentage of Outstanding Common Shares (1) OPKO Health, Inc. 2,171,674 8.06% ______________ (1) Based on 26,935,897 shares of GeneDx Common Stock of the Issuer outstanding on July 22, 2024, as set forth in the Issuer's Form 10-Q filed with the SEC on July 30, 2024. (b) Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5. (c) In the last 60 days prior to the filing of this Amendment No. 7, OPKO sold a total of 1,211,729 shares of GeneDx Common Stock on the open market at prices ranging from $29.00 to $38.59 per share for an aggregate sale price of approximately $41,649,375. Sales of GeneDx Common Stock prior to August 26, 2024 were previously reported in Amendment No. 4, Amendment No. 5, and Amendment No. 6. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days. Date Shares of Common Stock Aggregate Purchase Price Weighted Price Per Share 7/22/24 50,000 $ 1,630,422 $ 32.6088 7/23/24 75,000 $ 2,509,248 $ 33.4566 7/24/24 75,000 $ 2,529,102 $ 33.7214 7/26/24 60,000 $ 2,031,255 $ 33.8543 CUSIP No. 81663L200 Schedule 13D PAGE 4 of 5 7/29/24 50,000 $ 1,692,890 $ 33.8578 7/31/24 88,839 $ 2,976,350 $ 33.5027 8/6/24 12,994 $ 381,427 $ 29.3541 8/8/24 100,000 $ 3.182.380 $ 31.8238 8/12/24 59,787 $ 2,029,811 $ 33.9507 8/13/24 24,987 $ 868,502 $ 34.7582 8/15/24 39,824 $ 1,317,506 $ 33.0832 8/16/24 50,000 $ 1,714,851 $ 34.2970 8/19/24 50,000 $ 1,724,519 $ 34.4904 8/21/24 94,826 $ 3,270,681 $ 34.4914 8/22/24 25,000 $

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. OPKO Health, Inc. Dated: September 18, 2024 By: /s/ Steven D. Rubin Name: Steven D. Rubin Title: Executive Vice President - Administration

View Full Filing

View this SC 13D/A filing on SEC EDGAR